Myeloproliferative neoplasms: open trials in Belgium

15 open trials have a site in Belgium. Registry data; only the trial team decides who can take part.

NCT07357727
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Trial Treatment · Phase 3 · Novartis Pharmaceuticals
Ziekenhuis Aan De Stroom, Antwerp · Algemeen Ziekenhuis Delta, Roeselare · Cliniques Universitaires Saint-Luc, Sint-Lambrechts-Woluwe
Registry updated 2026-11-06
NCT07623161
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
Trial Treatment · Phase 3 · Takeda
Ziekenhuis Aan De Stroom, Antwerp · Chu Helora, La Louvière · UZ Leuven, Leuven · Algemeen Ziekenhuis Delta, Roeselare · Centre Hospitalier Universitaire Dinant Godinne Sainte-Elisabeth-UCL-Namur, Yvoir
Registry updated 2026-11-06
NCT07623200
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
Trial Treatment · Phase 3 · Incyte Corporation
Jules Bordet lnstitute, Anderlecht · Centre Hospitalier Universitaire (Chu) Brugmann (Brugmann University Hospital (Uh)) - Victor Horta, Brussels · Universitair Ziekenhuis Leuven, Leuven · Centre Hospitalier Universitaire de Liege - Sart Tilman, Liège · Algemeen Ziekenhuis Deltaaretaie, Roeselare · Universite Catholique de Louvain (Ucl) - Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert
Registry updated 2026-11-05
NCT07441694
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Trial Treatment · Phase 1 · Incyte Corporation
Centre Hospitalier Universitaire (CHU) de Liege, Liège · AZ Delta, Roeselare
Registry updated 2026-10-30
NCT04176198
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Trial Treatment · Phase 1/2 · Sumitomo Pharma America, Inc.
Het Ziekenhuisnetwerk Antwerpen, Antwerp · Universitair Ziekenhuis Gent, Gent · UZ Leuven, Leuven · Centre Hospitalier Universitaire de Liège, Liège
Registry updated 2026-10-02
2024-511309-47-00
A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate thrombocytopenia.
Trial Treatment · Phase 2 · Karyopharm Therapeutics Inc.
Universitair Ziekenhuis Gent, Gent · UZ Leuven, Leuven
Registry updated 2026-09-25
NCT04996875
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Trial Treatment · Phase 2 · Cogent Biosciences, Inc.
CHU de Liège, Liège
Registry updated 2026-09-15
2023-504724-25-00
Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis
Trial Treatment · Phase 3 · Kartos Therapeutics Inc.
Het Ziekenhuisnetwerk Antwerpen, Antwerp · UZ Leuven, Leuven · Centre Hospitalier Universitaire de Liège, Liège · Algemeen Ziekenhuis Delta, Roeselare · Centre Hospitalier Universitaire Dinant Godinne Sainte-Elisabeth-UCL-Namur, Yvoir
Registry updated 2026-09-14
NCT07008118
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
Trial Treatment · Phase 1 · Incyte Corporation
Cliniques universitaires Saint-Luc, Brussels · Universitair Ziekenhuis Gent, Ghent · Universitaire Ziekenhuizen Leuven, Leuven
Registry updated 2026-08-06
NCT04064060
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Trial Treatment · Phase 3 · Celgene
Brasschaat · Bruges · Ghent · Leuven
Registry updated 2026-07-01
NCT07590986
Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative Neoplasm
Research · Université Catholique de Louvain
de Duve Institute, UCLouvain, Brussels
Registry updated 2026-05-15
NCT05980806
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
Trial Treatment · Phase 2 · Karyopharm Therapeutics Inc
UZ Gent, Ghent · Uz Leuven Campus Gasthuisberg, Leuven
Registry updated 2026-02-12
NCT06401356
An extension study for patients previously enrolled in studies with pelabresib
Trial Treatment · Phase 3 · Novartis Pharma AG
Het Ziekenhuisnetwerk Antwerpen, Antwerp · Az St-Jan Brugge-Oostende A.V., Brugge
Registry updated 2026-01-28
NCT06479135
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Trial Treatment · Phase 3 · Kartos Therapeutics, Inc.
Antwerp Hospital Network (ZNA) Cadix, Antwerp · University Hospitals Leuven, Campus Gasthuisberg, Leuven · University Hospital Center Sart-Tilman, Liège · General Hospital Delta, Roeselare · UCL Mont-Godinne University Hospitals, Yvoir
Registry updated 2025-09-25
NCT03852407
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning
Trial Treatment · Phase 2 · University of Liege
Institut Jules Bordet, Anderlecht · Ziekenhuis Aan De Stroom, Antwerp · Az St-Jan Brugge-Oostende A.V., Brugge · Universiteit Gent, Gent · Vrije Universiteit Brussel, Jette · UZ Leuven, Leuven · Algemeen Ziekenhuis Delta, Roeselare · Cliniques Universitaires Saint-Luc, Sint-Lambrechts-Woluwe · Centre Hospitalier Universitaire Dinant Godinne Sainte-Elisabeth-UCL-Namur, Yvoir
Registry updated 2022-10-12

All Myeloproliferative neoplasms trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error